Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis

New England Journal of Medicine

Volumn 374, Issue 2, 2016, Pages 124-134

  Heemskerk, A Dorothee ^a,d   Bang, Nguyen D ^a,b   Mai, Nguyen T H ^a   Chau, Tran T H ^a   Phu, Nguyen H ^a,c   Loc, Pham P ^c   Chau, Nguyen V V ^c   Hien, Tran T ^a   Dung, Nguyen H ^b   Lan, Nguyen T N ^b   Lan, Nguyen H ^b   Lan, Nguyen N ^b   Phong, Le T ^b   Vien, Nguyen N ^b   Hien, Nguyen Q ^b   Yen, Nguyen T B ^a,b   Ha, Dang T M ^a,b   Day, Jeremy N ^a,d   Caws, Maxine ^e   Merson, Laura ^a,d   Thinh, Tran T V ^a   Wolbers, Marcel ^a,d   Thwaites, Guy E ^a,d   Farrar, Jeremy J ^a,d   more..

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b Pham Ngoc Thach Hospital   (Viet Nam)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INTENSIFICATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUBERCULOUS MENINGITIS; VIET NAM; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTIC RESISTANCE; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; TUBERCULOSIS, MENINGEAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LEVOFLOXACIN; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROPORTIONAL HAZARDS MODELS; RIFAMPIN; TUBERCULOSIS, MENINGEAL;

EID: 84954286992     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1507062     Document Type: Article

References (29)

1. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol 2013; 12: 999-1010.
2. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008; (1): CD002244.
3. Treatment of tuberculosis guidelines. 4th ed. Geneva: World Health Organization, 2010 (http://apps .who .int/iris/bitstream/10665/44165/1/9789241547833-eng.pdf).
4. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009; 59: 167-87.
5. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb) 2010; 90: 279-92.
6. Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992; 29: 719-24.
7. Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Respir Dis 1993; 148: 650-5.
8. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 2007; 51: 2546-51.
9. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013; 13: 27-35.
10. Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother 2011; 55: 3244-53.
11. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852-7.
12. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-12.
13. Heemskerk D, Day J, Chau TT, et al. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. Trials 2011; 12: 25.
14. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis 2010; 10: 803-12.
15. Ardito F, Posteraro B, Sanguinetti M, Zanetti S, Fadda G. Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2001; 39: 4440-4.
16. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741-51.
17. Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-Associated tuberculous meningitis. Clin Infect Dis 2011; 52: 1374-83.
18. Medical Research Council. Streptomycin treatment of tuberculous meningitis. Lancet 1948; 1: 582-96.
19. Török ME, Nguyen DB, Tran TH, et al. Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One 2011; 6(12): e27821.
20. R Core Team. R: A language and environment for statistical computing. 2015 (http://www.R-project.org/).
21. Wolbers M, Heemskerk D, Chau TT, et al. Sample size requirements for separating out the effects of combination treatments: randomised controlled trials of combination therapy vs. standard treatment compared to factorial designs for patients with tuberculous meningitis. Trials 2011; 12: 26.
22. Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015; 191: 1058-65.
23. Te Brake L, Dian S, Ganiem AR, et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents 2015; 45: 496-503.
24. Donald PR. The chemotherapy of tuberculous meningitis in children and adults. Tuberculosis (Edinb) 2010; 90: 375-92.
25. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 796-806.
26. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005; 171: 699-706.
27. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371: 1577-87.
28. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371: 1599-608.
29. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371: 1588-98.